Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA)
LQDA shareholders who lost money after a court found that Yutrepia infringed two valid United Therapeutics patent claims may have the right to seek recovery. The investigation includes Liquidia's forecast of more than $1 billion in 2027 net revenue. NEW YORK, Oct. 5, 2026 /PRNewswire/ --...
Covered in this story
Analyst targets on Liquidia Corp
- Wells Fargo: $28.6 → $30 by Oct 2027 · Equal Weight via Seeking Alpha
- H.C. Wainwright: $28.6 → $58 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $LQDA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Liquidia Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.